In its latest 10-Q filing, Transcode Therapeutics disclosed critical developments including an imminent Nasdaq listing deficiency notice tied to stockholders' equity shortfall, offset by a new Standby Equity Purchase Agreement (SEPA) with Yorkville enabling up to $14 million in capital raises. The company's lead RNA cancer therapy candidate, TTX-MC138, is progressing from Phase 1 into a Phase 2a trial under the Quantum Leap PRE-I-SPY platform, with pipeline expansion via acquisition of Polynoma. Despite clinical momentum supported by seasoned leadership, the company faces acute funding pressures and potential delisting risks that may constrain near-term operations and growth execution.